HK1245125A1 - 包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器 - Google Patents

包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器 Download PDF

Info

Publication number
HK1245125A1
HK1245125A1 HK18104726.3A HK18104726A HK1245125A1 HK 1245125 A1 HK1245125 A1 HK 1245125A1 HK 18104726 A HK18104726 A HK 18104726A HK 1245125 A1 HK1245125 A1 HK 1245125A1
Authority
HK
Hong Kong
Prior art keywords
fluticasone propionate
dry powder
dose
powder inhaler
patient
Prior art date
Application number
HK18104726.3A
Other languages
English (en)
Chinese (zh)
Inventor
Mukul Dalvi
Seah Kee Tee
Original Assignee
Teva Branded Pharmaceutical Products R&D, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55443303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1245125(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Branded Pharmaceutical Products R&D, Inc. filed Critical Teva Branded Pharmaceutical Products R&D, Inc.
Publication of HK1245125A1 publication Critical patent/HK1245125A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
    • A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
    • A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18104726.3A 2015-01-20 2016-01-20 包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器 HK1245125A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562105479P 2015-01-20 2015-01-20
US62/105,479 2015-01-20
PCT/US2016/014072 WO2016118589A1 (en) 2015-01-20 2016-01-20 Dry powder inhaler comprising fluticasone propionate and salmeterol xinafoat

Publications (1)

Publication Number Publication Date
HK1245125A1 true HK1245125A1 (zh) 2018-08-24

Family

ID=55443303

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18104726.3A HK1245125A1 (zh) 2015-01-20 2016-01-20 包含丙酸氟替卡松和昔萘酸沙美特罗的干粉吸入器

Country Status (19)

Country Link
US (2) US20180015035A1 (cg-RX-API-DMAC7.html)
EP (1) EP3247331A1 (cg-RX-API-DMAC7.html)
JP (1) JP2018503687A (cg-RX-API-DMAC7.html)
KR (1) KR20170103975A (cg-RX-API-DMAC7.html)
CN (1) CN107530357A (cg-RX-API-DMAC7.html)
AR (1) AR104771A1 (cg-RX-API-DMAC7.html)
AU (2) AU2016209363B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017015353A2 (cg-RX-API-DMAC7.html)
CA (1) CA2974125A1 (cg-RX-API-DMAC7.html)
CL (1) CL2017001859A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017008395A2 (cg-RX-API-DMAC7.html)
EA (1) EA201791632A1 (cg-RX-API-DMAC7.html)
HK (1) HK1245125A1 (cg-RX-API-DMAC7.html)
IL (1) IL253499A0 (cg-RX-API-DMAC7.html)
MA (1) MA41378A (cg-RX-API-DMAC7.html)
MX (2) MX383344B (cg-RX-API-DMAC7.html)
PE (1) PE20171258A1 (cg-RX-API-DMAC7.html)
TW (1) TW201628607A (cg-RX-API-DMAC7.html)
WO (1) WO2016118589A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3054920T3 (pl) * 2013-10-07 2021-07-05 Teva Branded Pharmaceutical Products R&D, Inc. Inhalator suchego proszku
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol
EP3552646B1 (en) 2016-11-18 2021-07-07 Norton (Waterford) Limited Drug delivery device with electronics
CN110201280B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药装置的吸嘴和吸入给药装置
CN110201281B (zh) * 2018-02-28 2021-08-06 张江 吸入给药装置和吸入给药组合结构
CN110201278B (zh) * 2018-02-28 2021-07-30 张江 用于吸入给药的药盒和吸入给药组合结构
CN110064110A (zh) * 2019-05-29 2019-07-30 上海理工大学 一种容积旋钮式干粉储存吸入装置
GB2585206B (en) * 2019-07-01 2021-08-11 Merxin Ltd Portable inhaler

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
TWI224513B (en) 2000-06-23 2004-12-01 Norton Healthcare Ltd Dose counter for medicament inhaler
PE20020067A1 (es) * 2000-06-23 2002-02-05 Norton Healthcare Ltd Desaglomerador para inhalador de polvo seco accionado por la respiracion
AR030516A1 (es) * 2000-08-31 2003-08-20 Glaxo Group Ltd Uso de una combinacion de salmeterol y fluticasona
EP2283817B1 (en) * 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
CN1694689A (zh) 2002-09-30 2005-11-09 阿库斯菲尔公司 供吸入的缓释多孔微粒
US9114081B2 (en) * 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
PT2435025T (pt) * 2009-05-29 2016-11-11 Pearl Therapeutics Inc Administração, por via respiratória, de agentes activos
CN102573886A (zh) * 2009-09-17 2012-07-11 相互制药公司 用抗病毒剂治疗哮喘的方法
GB0919465D0 (en) 2009-11-06 2009-12-23 Norton Healthcare Ltd Airflow adaptor for a breath-actuated dry powder inhaler
DK2502644T3 (en) * 2010-05-18 2015-02-02 Ivax Pharmaceuticals Ireland Dosistællere for inhalers, inhalers and shafts thereof
WO2011145109A1 (en) 2010-05-20 2011-11-24 Sun Pharma Advanced Research Company Ltd., Dry powder inhalation composition
KR20130140358A (ko) * 2012-06-14 2013-12-24 한미약품 주식회사 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
EP2991626A1 (en) * 2013-04-29 2016-03-09 Sanofi SA Inhalable pharmaceutical compositions and the inhaler devices containing them
JP6387397B2 (ja) * 2013-05-03 2018-09-05 ダウ グローバル テクノロジーズ エルエルシー 平衡制約反応のためのプロセス
PL3054920T3 (pl) 2013-10-07 2021-07-05 Teva Branded Pharmaceutical Products R&D, Inc. Inhalator suchego proszku
BR112017007587A2 (pt) * 2014-10-16 2018-01-30 Teva Branded Pharmaceutical Products R&D Inc processo para preparar uma formulação farmacêutica em pó seca e inalável
MA41378A (fr) * 2015-01-20 2017-11-28 Teva Branded Pharmaceutical Prod R & D Inc Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol

Also Published As

Publication number Publication date
TW201628607A (zh) 2016-08-16
EP3247331A1 (en) 2017-11-29
CN107530357A (zh) 2018-01-02
US20160206559A1 (en) 2016-07-21
KR20170103975A (ko) 2017-09-13
BR112017015353A2 (en) 2018-01-16
CL2017001859A1 (es) 2018-04-06
MX383344B (es) 2025-03-13
CO2017008395A2 (es) 2018-01-05
US20180015035A1 (en) 2018-01-18
AR104771A1 (es) 2017-08-16
PE20171258A1 (es) 2017-08-28
EA201791632A1 (ru) 2017-12-29
MX2021006751A (es) 2021-07-15
WO2016118589A1 (en) 2016-07-28
MX2017009122A (es) 2017-10-12
MA41378A (fr) 2017-11-28
IL253499A0 (en) 2017-09-28
US9415008B2 (en) 2016-08-16
JP2018503687A (ja) 2018-02-08
AU2016209363A1 (en) 2017-08-24
CA2974125A1 (en) 2016-07-28
AU2016209363B2 (en) 2021-02-04
AU2021202784A1 (en) 2021-05-27

Similar Documents

Publication Publication Date Title
HK1222127A1 (zh) 乾粉吸入器
MX2021006751A (es) Inhalador de polvo seco con propionato de fluticasona y xinafoato de salmeterol.
HK1198279A1 (en) Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
MX2013012975A (es) Composiciones farmaceuticas.
WO2009065406A3 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
MX360045B (es) Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
WO2014064410A3 (en) Pharmaceutical composition comprising tiotropium and a hydrofluoroalkane
WO2012040228A3 (en) Aerosol composition for administering drugs
MX2014004364A (es) Composiciones que comprenden sulfato de salbutamol.
MX2019003685A (es) Composicion farmaceutica para uso en el tratamiento terapeutico del cancer y complicaciones del cancer.
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX370890B (es) Composición que comprende sulfato de salbutamol.
MX2015015132A (es) Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
WO2013104892A8 (en) Application of high dose compounds via inhalation
HK1255584A1 (zh) 使用阿坎酸及d-环丝胺酸的联合疗法
WO2012042197A3 (en) Low dose pharmaceutical composition comprising zanamivir
HK1222585A1 (zh) 用於提供疼痛减轻和麻醉的二氢埃托啡
WO2016122288A3 (ko) 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
WO2015130963A3 (en) Compositions and methods for administering insulin or insulin-like protein to the brain
WO2014170820A3 (en) A pharmaceutical combination for treating tuberculosis
TH173838A (th) เครื่องพ่นละอองยาผงแห้ง
HK1225969A1 (zh) 利用低剂量的拉喹莫德治疗克隆氏病
WO2014016613A3 (en) Type b lantibiotic nvb302 for the treatment of c. difficile infection